Health Times reporter Wang Zhenya
"From the current point of view, the spread rate and lethality of the Omicron mutant strain are not optimistic. The combination of ambavir monoclonal antibody/romizumab will play a very important role in the early treatment of severely ill COVID-19 patients. On December 21, at the press conference on the sharing of experimental data on the "Omilkejung" mutant strain by amphavir monoclonal antibody/romizumab combination therapy, Professor Zhang Linqi of Tsinghua University School of Medicine introduced.
"There are now patients infected with the Omiljung variant in China, and some patients are still infected with the mutant strain of the virus after vaccination." Luo Yongqing, CEO of Tengsheng Huachuang, introduced to the Health Times reporter that dual antibody drugs are suitable for people with poor vaccine protection, and new crown drugs are a supplement to vaccines.
After the global discovery of the Omiljung mutant strain, Tengsheng Huachuang was the first to carry out experiments on omilcroon in multiple independent laboratories around the world.
Dr. Zhu Qing, senior vice president of Tengsheng Bo Pharmaceutical and head of the biopharmaceutical department, introduced that the latest public data summary of the National Institutes of Health (NIH) shows that romizumab is one of the few antibodies that neutralizes the activity of all monoclonal antibodies and is not affected by Omiqueron, and the evaluation results of multiple laboratories around the world are consistent. Therefore, the combination of ampavirinumab/romizumab maintains a good neutralization activity on Omiqueron, which has obvious advantages over other antibody products.
"Nearly 10 new coronavirus variants, such as the British alpha variant, the South African beta variant, and the Indian Delta, will not affect the activity of the first COVID-19 drug." Dr. Zhu Qing further introduced to the Health Times reporter that romisvirumab is the only antibody that neutralizes the activity of all the monoclonal antibodies currently under research and approval that is not affected by Omiqueron, and the data shows that our new crown drugs have great advantages in the treatment of mutant strains of infected people.
In addition, previous clinical trial data show that patients receive antibody therapy in the later stages. Dr. Zhu Qing introduced, and at this point, China's new crown drugs also have advantages, new crown drugs have been optimized for half-life extension, patients within 10 days of illness, receiving antibody therapy can be effectively alleviated, reducing hospitalization and mortality. Currently, the combination of covid-19 drugs amphavicumab/romizumab can reduce hospitalization/mortality by up to 80%.
Compared with the globally listed new crown drugs, the third phase of clinical trial data, China's new crown drugs are the only drugs in the world, not only the early treatment is effective, but also the late treatment also has a good effect. "COVID-19 drugs are not necessary for all patients." Professor Zhang Linqi stressed that the key population we treat is a high-risk group, which has entered the population with severe illness and close to death. At the same time, due to the optimization of the drug administration mode, the highest drug concentration can be quickly reached after intravenous injection, and the best treatment opportunity can be seized to maintain a stable high blood concentration for several weeks after taking the drug. The results of this experiment have good data, and the new crown drug is effective in the treatment of patients with mutant strains.